Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles

• Status: Unknown status
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Choriogonadotropin alfa (Ovidrel®) is a recombinant hCG (rhCG) preparation derived from genetically engineered Chinese hamster ovary cells, which is widely used for final oocyte maturation triggering in assisted reproductive technology (ART).Recombinant hCG has been investigated about its safety and efficacy comparing with urinary hCG, but still the optimal dose of rhCG is questionable. From former studies, there only have been proven that high dose of hCG can make ovarian hyperstimulation syndrome (OHSS) in usual condition. On the other hand, we hypothesize that high dose of hCG may improve oocyte maturity in poor responders who cannot easily provoke OHSS. Hence, this study will assess the comparative efficacy and safety of 250mcg and 500mcg of rhCG in ART treatment cycle.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Chorionic Gonadotropin

Criteria

Inclusion Criteria:

• poor response in prior IVF cycle (≤ 4 oocyte retrieved)

• women's age ≥ 40 years

• FSH ≥ 10mIU/mL or AMH ≤ 1.1ng/mL

• Antral follicle count <6

Exclusion Criteria:

• patient without informed consent